Applied Biosystems Introduces new Real-time PCR Solution to Quantitate Host Cell DNA Impurities
Read time:
Applied Biosystems has announced the launch of the life science industry’s first integrated real-time PCR solution for measuring residual DNA impurities from Chinese Hamster Ovary (CHO) host cells.
The new solution can enhances the ability of biopharmaceutical companies to quantitate the impurities. The CHO cell lines are the primary medium used by biopharmaceutical companies to develop biological drugs, which are designed to treat a variety of medical conditions, including cancer, cardiovascular disease, inflammatory diseases, multiple sclerosis and viral infection.
The resDNASEQ™ CHO Residual DNA Quantitation and PrepSEQ™ Sample Preparation kits are the latest additions to the SEQ portfolio of molecular methods for pharmaceutical manufacturing. The new solution combines DNA isolation technology in a magnetic bead-based kit for high DNA recovery with a qPCR assay, including a genomic CHO standard for generating specific quantitation data.
Expanding the SEQ portfolio to include residual DNA quantitation is expected to broaden the use of Applied Biosystems real-time PCR technologies in pharmaceutical manufacturing. The new products complement other molecular detection solutions that include the MicroSEQ® Microbial Identification System and MicroSEQ® Mycoplasma Detection System, which are now routinely used by analytical groups supporting large-scale pharmaceutical manufacturing.
The new solution can enhances the ability of biopharmaceutical companies to quantitate the impurities. The CHO cell lines are the primary medium used by biopharmaceutical companies to develop biological drugs, which are designed to treat a variety of medical conditions, including cancer, cardiovascular disease, inflammatory diseases, multiple sclerosis and viral infection.
The resDNASEQ™ CHO Residual DNA Quantitation and PrepSEQ™ Sample Preparation kits are the latest additions to the SEQ portfolio of molecular methods for pharmaceutical manufacturing. The new solution combines DNA isolation technology in a magnetic bead-based kit for high DNA recovery with a qPCR assay, including a genomic CHO standard for generating specific quantitation data.
Expanding the SEQ portfolio to include residual DNA quantitation is expected to broaden the use of Applied Biosystems real-time PCR technologies in pharmaceutical manufacturing. The new products complement other molecular detection solutions that include the MicroSEQ® Microbial Identification System and MicroSEQ® Mycoplasma Detection System, which are now routinely used by analytical groups supporting large-scale pharmaceutical manufacturing.
Advertisement
